The age related vision dysfunction market size is projected to expand from USD 4.40 billion in 2025 and USD 4.67 billion in 2026 to USD 6.25 billion by 2031, registering a CAGR of 6.03% between 2026 to 2031. This report is Segmented by Dysfunction Type (Cataract, AMD, Glaucoma, Presbyopia, Diabetic Retinopathy, Low Vision), Product (Prescription Drug, Surgical Device), Treatment Modality (Pharmacological, Surgical), End User (Hospitals, Ophthalmology Clinics, Ascs, Retail Optometry, Others), and Geography (North America, Europe, Asia-Pacific, MEA, South America). Forecasts are in Value (USD).
Alcon completed its acquisition of BELKIN Vision in July 2024, adding direct selective laser trabeculoplasty technology for glaucoma care. The transaction included USD 81 million in upfront consideration and up to USD 385 million in sales-based milestones. AMD remains a major revenue contributor due to anti-VEGF treatment intensity and specialized care needs, while geographic atrophy therapies, presbyopia drops, diabetic retinopathy care, and low-vision technologies broaden the age-related vision dysfunction market.
Prescription drugs held 64.34% of revenue in 2025, reflecting the established value of anti-VEGF biologics and chronic glaucoma therapy. Surgical devices are projected to expand at a CAGR of 9.80% through 2031, outpacing the overall age-related vision dysfunction market. Premium IOL adoption, glaucoma device volumes, and femtosecond laser-assisted cataract surgery support this growth.
Alcon’s LENSAR acquisition added a robotic cataract laser platform and strengthened its position in surgical devices. The prescription drug segment faces tougher pricing pressure as ranibizumab and aflibercept biosimilars become available. Formycon’s May 2026 European Union launch of Ahzantive and Baiama marked another step in aflibercept biosimilar competition, while protected implant designs and integrated procedure platforms help device manufacturers maintain pricing.
Europe is the second-largest regional contributor to the age-related vision dysfunction market, with Germany and the United Kingdom among its largest national markets. Regional reimbursement systems support standard care but apply detailed benefit and price assessments to newer medicines, while biosimilar availability supports cost-containment priorities. Formycon’s Ahzantive and Baiama became available in the European Union in May 2026. Differences in formulary rules and physician prescribing patterns across France, Italy, Spain, and other European countries can slow premium biologic adoption, while implant and IOL regulations favor established certified manufacturers.
Asia-Pacific is projected to record the highest regional CAGR of 8.58% through 2031, supported by China’s 260 million seniors and India’s expanding urban patient base. South Asia had an age-standardized cataract prevalence of 17,756.6 per 100,000 older adults in GBD 2021 research, while Japan maintained high cataract procedure volumes through universal health coverage despite more limited patient payment for premium IOLs.
Global Age Related Vision Dysfunction Market Trends and Insights
Population Aging and Rising Disease Prevalence
Population aging remains a key demand driver for the age-related vision dysfunction market, as it expands the patient base at risk of multiple vision conditions. The global population aged 60 years and older is projected to increase from nearly 1 billion in 2024 to more than 2 billion by 2050. GBD 2024 research projects cataract prevalence among adults aged 60 years and older to reach 160.8 million to 211.4 million cases by 2050, with 87.4% of the additional burden attributed to population growth rather than higher incidence rates. Among people aged 70 to 74 years, the age-standardized prevalence of blindness and visual impairment increased at an average annual rate of 1.02% between 1990 and 2021, with lower-income settings offering significant scope for scalable diagnosis, cataract surgery, and affordable chronic treatment.Anti-VEGF Expansion and Long-Acting Retinal Delivery
Anti-VEGF therapy remains central to retinal care in the age-related vision dysfunction market, particularly for AMD and related retinal conditions. Biosimilar entry is reducing treatment costs and can improve patient access in markets where originator therapies have limited adoption. Formycon launched the aflibercept biosimilars Ahzantive and Baiama in the European Union in May 2026 after a March 2026 settlement with Regeneron and Bayer, and it secured a US launch window for Q4 2026 or earlier through a separate October 2025 agreement with Regeneron. Longer-duration delivery formats can reduce injection frequency and follow-up burden, supporting access, specialist distribution, and sustained treatment adherence.High Out-of-Pocket Burden and Uneven Reimbursement
Reimbursement rules directly influenced patient access to products in the age related vision dysfunction market. Established systems commonly covered standard cataract surgery, while premium IOL upgrades often required direct patient payment. Biosimilar competition improved access to retinal treatment but continued to pressure originator revenue. In China and India, broader support for basic cataract extraction than for premium IOLs and anti-VEGF biologics limited revenue per procedure, making localized pricing and payment models critical.Other drivers and restraints analyzed in the detailed report include:
- Premium Intraocular Lens Adoption and Spectacle Independence Demand
- Screening, Imaging, and Tele-Ophthalmology for Earlier Diagnosis
- Ophthalmic Workforce, Surgical Capacity, and Follow-Up Constraints
Segment Analysis
Cataract accounted for 38.66% of revenue in 2025, making it the largest dysfunction category. The segment benefited from a large procedure base and revenue gains linked to premium intraocular lens (IOL) adoption. Alcon cited approximately 32 million cataract procedures each year worldwide in its 2025 LENSAR announcement. Glaucoma is projected to record the highest CAGR of 8.15% through 2031, supported by earlier intervention, minimally invasive glaucoma surgery, direct selective laser trabeculoplasty, and chronic drug therapy.Alcon completed its acquisition of BELKIN Vision in July 2024, adding direct selective laser trabeculoplasty technology for glaucoma care. The transaction included USD 81 million in upfront consideration and up to USD 385 million in sales-based milestones. AMD remains a major revenue contributor due to anti-VEGF treatment intensity and specialized care needs, while geographic atrophy therapies, presbyopia drops, diabetic retinopathy care, and low-vision technologies broaden the age-related vision dysfunction market.
Prescription drugs held 64.34% of revenue in 2025, reflecting the established value of anti-VEGF biologics and chronic glaucoma therapy. Surgical devices are projected to expand at a CAGR of 9.80% through 2031, outpacing the overall age-related vision dysfunction market. Premium IOL adoption, glaucoma device volumes, and femtosecond laser-assisted cataract surgery support this growth.
Alcon’s LENSAR acquisition added a robotic cataract laser platform and strengthened its position in surgical devices. The prescription drug segment faces tougher pricing pressure as ranibizumab and aflibercept biosimilars become available. Formycon’s May 2026 European Union launch of Ahzantive and Baiama marked another step in aflibercept biosimilar competition, while protected implant designs and integrated procedure platforms help device manufacturers maintain pricing.
Complete Report Scope:
- By Dysfunction Type
- Cataract
- Age-Related Macular Degeneration
- Glaucoma
- Presbyopia
- Age-Associated Diabetic Retinopathy
- Age-Associated Low Vision and Vision Rehabilitation
- By Product
- Prescription Drug
- Surgical Device
- By Treatment Modality
- Pharmacological Treatment
- Anti-VEGF and Other Retinal Biologics
- Prostaglandin Analogues, Beta-Blockers, and Combination Drops
- Miotics and Presbyopia Eye Drops
- Nutritional and Supportive Therapies
- Surgical Treatment
- Cataract Extraction and Intraocular Lens Implantation
- Trabeculectomy and Tube Shunt Surgery
- Minimally Invasive Glaucoma Surgery
- Retinal and Vitreoretinal Surgery
- Refractive and Presbyopia-Correcting Procedures
- Laser and Photodynamic Treatment
- Low-Vision Rehabilitation and Assistive Care
- Pharmacological Treatment
- By End User
- Hospitals
- Ophthalmology Clinics
- Ambulatory Surgery Centers
- Retail Optometry and Optical Practices
- Others
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America held 41.22% of the age-related vision dysfunction market share in 2025, supported by high ophthalmic spending, advanced diagnostics, and strong demand for premium cataract services. The United States accounted for an estimated 36% of global premium cataract surgery manufacturer revenue, with recent approvals and launches spanning prescription drugs, biosimilars, and premium IOLs. Canada sustained standard cataract and glaucoma volumes through public coverage, while Mexico’s private ophthalmology network added premium surgical capacity and supported cross-border patient flows. The projected 30% US ophthalmology workforce inadequacy by 2035 remained a practical limit on procedure capacity, though artificial intelligence-supported planning and optometrist-led triage helped providers manage demand.Europe is the second-largest regional contributor to the age-related vision dysfunction market, with Germany and the United Kingdom among its largest national markets. Regional reimbursement systems support standard care but apply detailed benefit and price assessments to newer medicines, while biosimilar availability supports cost-containment priorities. Formycon’s Ahzantive and Baiama became available in the European Union in May 2026. Differences in formulary rules and physician prescribing patterns across France, Italy, Spain, and other European countries can slow premium biologic adoption, while implant and IOL regulations favor established certified manufacturers.
Asia-Pacific is projected to record the highest regional CAGR of 8.58% through 2031, supported by China’s 260 million seniors and India’s expanding urban patient base. South Asia had an age-standardized cataract prevalence of 17,756.6 per 100,000 older adults in GBD 2021 research, while Japan maintained high cataract procedure volumes through universal health coverage despite more limited patient payment for premium IOLs.
List of Companies Covered in this Report:
- Abbvie
- Alcon
- Apellis Pharmaceuticals, Inc.
- Astellas Pharma
- Bausch + Lomb Corporation
- Bayer
- Carl Zeiss
- Eyenovia, Inc.
- Genentech
- Glaukos
- Johnson & Johnson
- Kodiak Sciences Inc.
- Novartis
- Ocular Therapeutix, Inc.
- Orasis Pharmaceuticals, Inc.
- Outlook Therapeutics, Inc.
- Regeneron Pharmaceuticals
- Santen Pharmaceuticals
- Visus Therapeutics, Inc.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 INTRODUCTION
4 MARKET LANDSCAPE
5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)
6 COMPETITIVE LANDSCAPE
7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Alcon Inc.
- Apellis Pharmaceuticals, Inc.
- Astellas Pharma Inc.
- Bausch + Lomb Corporation
- Bayer AG
- Carl Zeiss Meditec AG
- Eyenovia, Inc.
- Genentech, Inc.
- Glaukos Corporation
- Johnson & Johnson
- Kodiak Sciences Inc.
- Novartis AG
- Ocular Therapeutix, Inc.
- Orasis Pharmaceuticals, Inc.
- Outlook Therapeutics, Inc.
- Regeneron Pharmaceuticals, Inc.
- Santen Pharmaceutical Co., Ltd.
- Visus Therapeutics, Inc.
